Information Provided By:
Fly News Breaks for January 13, 2020
Jan 13, 2020 | 08:08 EDT
Oppenheimer analyst Jay Olson raised his price target for Neurocrine to $132 from $115 following preliminary Q4 results. The analyst is encouraged by Ingrezza's continued launch performance and looks forward to 2020 expense guidance when full Q4 results are presented. Olson has an Outperform rating on the shares.
News For NBIX From the Last 2 Days
There are no results for your query NBIX